Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials
about
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaTreating Negative Symptoms in Schizophrenia: an UpdateSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeEfficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trialsLong-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trialsCost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Progress in compliance research and intervention: a commentary.Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study.Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled TrialsLong-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.Guidelines for the Pharmacotherapy of Schizophrenia in Adults.Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.Extrapyramidal Symptoms Probably Related to Risperidone Treatment: A Case Series.Improving outcomes of first-episode psychosis: an overview.Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS).Use of Transcranial Direct Stimulation in the Treatment of Negative Symptoms of Schizophrenia.Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.Effects of transcranial direct current stimulation on working memory and negative symptoms in schizophrenia: a phase II randomized sham-controlled trial.[Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].
P2860
Q24597701-7E98CC21-B2CE-44B5-9B4D-69404C7FDD6EQ26744805-B9E093E9-6C7E-4A80-9427-3B390EC1CD91Q26752965-7FB031D8-114B-4E85-B87F-E4A29D62AD8DQ26781173-5A25CFC3-B911-41DC-AA98-00014A2EDFE3Q28085407-DF3080BA-0171-459B-B8CD-25A5942A5794Q34418847-B7C9C195-A210-4FFC-9DE9-FB90FAE6D9E1Q35249595-59287EA1-41FB-4219-969C-8A8FE81AEC69Q36001512-20A8AA6D-2FD0-42B8-9E1B-0711A689FB35Q36698856-5EC03906-F081-4D9E-A873-A33E36C10041Q37236153-8F56AC64-DAD0-437E-95B7-1A20CA67CFA5Q37388354-7968E747-6CC7-4FAC-85BF-77B3CBFB2148Q37465729-C1BABEAC-8F0B-400E-9762-E0751DE4138DQ38206231-022F0BCD-DF0A-406C-92A6-173FDF1672CBQ38223569-5148890B-ADA7-4EA2-B60A-67D2FEFDE3E3Q38233228-BE631062-D6BC-44F5-9739-D00E49E74284Q38659006-557DA28A-7137-451C-8C43-1E908D8222FBQ38744570-D0704159-69D8-49B5-8FE1-C159AE7B1818Q38810163-45DCF08F-774A-491B-BDA6-7631F9982486Q38851123-224726D5-B711-4270-BD03-1C68F2B99898Q39432209-B0461F48-064C-40A2-A568-7E01FFE67A05Q40278766-5C261837-0497-4B11-925C-547F8D0CBDBCQ41485699-64E985DD-65AD-429F-9B99-C8CFCF92975AQ41658737-788458F1-A2B3-4A01-BECF-385A106CF32FQ45170470-48E7B314-2006-4212-9A54-7FEB7F1D539EQ47914703-EC3A155F-3AB4-403C-A519-971669A0D6A0Q50580108-54BBDADC-C49C-4252-943E-9D7609466D2AQ51738665-EF268C72-9643-4C09-9555-8E1443A74A7DQ53654663-75C6B502-ABC4-4BCD-A769-D940041F40FE
P2860
Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy and safety of second- ...... f randomized-controlled trials
@ast
Efficacy and safety of second- ...... f randomized-controlled trials
@da
Efficacy and safety of second- ...... f randomized-controlled trials
@en
Efficacy and safety of second- ...... f randomized-controlled trials
@en-gb
Efficacy and safety of second- ...... f randomized-controlled trials
@nl
type
label
Efficacy and safety of second- ...... f randomized-controlled trials
@ast
Efficacy and safety of second- ...... f randomized-controlled trials
@da
Efficacy and safety of second- ...... f randomized-controlled trials
@en
Efficacy and safety of second- ...... f randomized-controlled trials
@en-gb
Efficacy and safety of second- ...... f randomized-controlled trials
@nl
prefLabel
Efficacy and safety of second- ...... f randomized-controlled trials
@ast
Efficacy and safety of second- ...... f randomized-controlled trials
@da
Efficacy and safety of second- ...... f randomized-controlled trials
@en
Efficacy and safety of second- ...... f randomized-controlled trials
@en-gb
Efficacy and safety of second- ...... f randomized-controlled trials
@nl
P31
P50
P3181
P1476
Efficacy and safety of second- ...... f randomized-controlled trials
@en
P3181
P356
10.1097/YIC.0B013E32835B091F
P407
P577
2013-03-01T00:00:00Z